시장보고서

상품코드

1722528

황반변성 치료 시장 보고서 : 유형별, 병기별, 투여 경로별, 최종사용자별, 지역별(2025-2033년)

Macular Degeneration Treatment Market Report by Type, Stage of Disease, Route of Administration, End User, and Region 2025-2033

발행일: 2025년 05월 | 리서치사:

IMARC | 페이지 정보: 영문 149 Pages | 배송안내 : 2-3일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

황반변성 치료 세계 시장 규모는 2024년 99억 달러에 달했습니다. 향후 IMARC Group은 2033년에는 158억 달러에 달할 것으로 예상하며, 2025-2033년 연평균 성장률(CAGR)은 5.28%에 달할 것으로 전망하고 있습니다. 시장 성장의 주요 요인은 노화 황반변성 및 비만의 증가, 좌식 생활습관의 확산, 스마트 기기의 급속한 활용, 헬스케어 인프라의 대폭적인 개선 등이며, 특히 신흥 경제국에서 특히 두드러지게 나타나고 있습니다.

황반변성증은 신경 퇴행성 안질환으로 눈을 침범하여 시야의 중심부가 흐려지고 시력이 저하되는 질환입니다. 시야의 맹점, 시각의 왜곡, 어두운 곳에서 잘 보이지 않는 것이 특징입니다. 황반변성증의 치료법으로는 혈관신생억제제, 광선역학적 레이저 치료, 콘택트렌즈, 전이렌즈 등이 일반적으로 사용되고 있습니다. 레이저 치료는 안구의 환부에 전용 콘택트렌즈를 삽입하여 혈관과 함께 레이저로 봉합합니다. 혈관신생억제제는 혈관의 막힘이나 누출을 막기 위해 사용됩니다. 황반변성 치료의 적기 치료는 시력을 개선하고 만성 실명의 위험을 최소화하는 데 도움이 됩니다.

황반변성 치료 시장 동향:

노화 황반변성과 비만의 증가는 시장 성장을 촉진하는 주요 요인 중 하나입니다. 식습관의 변화와 좌식 생활습관의 증가는 황반변성증의 발병을 촉진하는 주요 요인으로 작용하고 있습니다. 또한, 스마트폰, 노트북, TV의 사용 증가로 인해 장시간 과도한 스크린 사용 시간이 증가함에 따라 이 질환의 발생에 영향을 미치고 있습니다. 또한, 비정상적인 혈관 발달을 막기 위해 아데노 부속 바이러스(AAV)를 체내에 주입하는 망막 유전자 치료제의 개발이 시장 성장을 촉진하고 있습니다. 이와 함께 의료 인프라의 대폭적인 개선은 시장 성장에 긍정적인 영향을 미치고 있습니다. 그 외의 요인으로는 혁신적이고 효과적인 약물 개발을 위한 광범위한 연구개발(R&D) 활동과 공중보건 증진을 위한 다양한 정부 이니셔티브의 시행 등이 시장 성장을 촉진할 것으로 예상됩니다.

본 보고서에서 다루는 주요 질문

2024년 세계 황반변성 치료 시장 규모는?
2025-2033년 황반변성 치료 세계 시장 성장률 전망은?
황반변성 치료 세계 시장을 이끄는 주요 요인은?
COVID-19가 황반변성 치료 세계 시장에 미치는 영향은?
황반변성 치료 세계 시장 유형별 분류는?
황반변성 치료 세계 시장에서의 병기별 분류는?
황반변성 치료 세계 시장 내 투여 경로별 분류는?
황반변성 치료 세계 시장 내 최종사용자별 분류는?
황반변성 치료 세계 시장 주요 지역은?
황반변성 치료 세계 시장의 주요 플레이어/기업은?

북미
- 미국
- 캐나다
아시아태평양
- 중국
- 일본
- 인도
- 한국
- 호주
- 인도네시아
- 기타
유럽
- 독일
- 프랑스
- 영국
- 이탈리아
- 스페인
- 러시아
- 기타
라틴아메리카
- 브라질
- 멕시코
- 기타
중동 및 아프리카
- 시장 내역 : 국가별

제11장 SWOT 분석

개요
강점
약점
기회
위협

제12장 밸류체인 분석

제13장 Porter's Five Forces 분석

개요
구매자의 교섭력
공급 기업의 교섭력
경쟁 정도
신규 참여업체의 위협
대체품의 위협

제14장 가격 분석

제15장 경쟁 구도

시장 구조
주요 기업
주요 기업 개요
- Aerie Pharmaceuticals Inc.
- Bausch Health Companies Inc.
- Bayer AG
- F. Hoffmann-La Roche Ltd
- Iveric Bio Inc.
- Novartis AG
- Panoptica
- Pfizer Inc.
- Phio Pharmaceuticals
- Regeneron Pharmaceuticals Inc.
- Regenxbio Inc.
- Santen Pharmaceutical Co. Ltd.

ksm 25.06.02

The global macular degeneration treatment market size reached USD 9.9 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 15.8 Billion by 2033, exhibiting a growth rate (CAGR) of 5.28% during 2025-2033. The market is majorly driven by the increasing incidences of age-related macular degeneration and obesity among the masses, growing prevalence of sedentary lifestyles, rapid utilization of smart devices, and significant improvements in the healthcare infrastructure, particularly in developing economies.

Macular degeneration is a neurodegenerative ocular disorder that affects the eyes and causes blurred or loss of vision in the center of the visual field. It is characterized by blind spots in the field of vision, visual distortions and inability to see in low light conditions. Some of the commonly used therapeutic techniques for macular degeneration includes anti-angiogenic drugs, photodynamic laser therapies, contact lenses and transitional lenses. Laser therapy involves the insertion of specialized contact lenses into the affected are of the eye, which are sealed by lasers along with the blood vessels. Anti-angiogenic drugs are used for preventing blockages and leakages in the blood vessels. Timely treatment of macular degeneration treatment can aid in enhancing vision and minimizing the risks of developing chronic blindness.

Macular Degeneration Treatment Market Trends:

The increasing incidences of age-related macular degeneration and obesity among the masses is one of the key factors driving the market growth. The changing dietary patterns and the rising adoption of sedentary lifestyles is leading to the development of macular degeneration. Additionally, the increasing utilization of smartphones, laptops and television, which is leading to prolonged and excessive screen time is also impacting the occurrence of the disorder. Moreover, the development of retinal gene therapies that involves the injection of adeno-associated virus (AAV) into the body for preventing the development of abnormal blood vessels is providing a thrust to the market growth. In line with this, significant improvements in the healthcare infrastructure is positively impacting the market growth. Other factors, including extensive research and development (R&D) activities for the development of innovative and effective drugs, along with the implementation of various government initiatives for promoting public health, are anticipated to drive the market toward growth.

Key Market Segmentation:

Breakup by Type:

Dry Age-related Macular Degeneration
Wet Age-related Macular Degeneration

Breakup by Stage of Disease:

Early Stage
Intermediate Stage
Late Stage

Breakup by Route of Administration:

Intravenous Route
Intravitreal Route

Breakup by End User:

Hospitals
Ambulatory Surgical Center
Others

Breakup by Region:

North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Aerie Pharmaceuticals Inc., Bausch Health Companies Inc., Bayer AG, F. Hoffmann-La Roche Ltd, Iveric Bio Inc., Novartis AG, Panoptica, Pfizer Inc., Phio Pharmaceuticals, Regeneron Pharmaceuticals Inc., Regenxbio Inc. and Santen Pharmaceutical Co. Ltd.

Key Questions Answered in This Report

1.What was the size of the global macular degeneration treatment market in 2024?
2.What is the expected growth rate of the global macular degeneration treatment market during 2025-2033?
3.What are the key factors driving the global macular degeneration treatment market?
4.What has been the impact of COVID-19 on the global macular degeneration treatment market?
5.What is the breakup of the global macular degeneration treatment market based on the type?
6.What is the breakup of the global macular degeneration treatment market based on the stage of disease?
7.What is the breakup of the global macular degeneration treatment market based on the route of administration?
8.What is the breakup of the global macular degeneration treatment market based on the end user?
9.What are the key regions in the global macular degeneration treatment market?
10.Who are the key players/companies in the global macular degeneration treatment market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

4.1 Overview
4.2 Key Industry Trends

5 Global Macular Degeneration Treatment Market

5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Type

6.1 Dry Age-related Macular Degeneration
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
6.2 Wet Age-related Macular Degeneration
- 6.2.1 Market Trends
- 6.2.2 Market Forecast

7 Market Breakup by Stage of Disease

7.1 Early Stage
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
7.2 Intermediate Stage
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
7.3 Late Stage
- 7.3.1 Market Trends
- 7.3.2 Market Forecast

8 Market Breakup by Route of Administration

8.1 Intravenous Route
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
8.2 Intravitreal Route
- 8.2.1 Market Trends
- 8.2.2 Market Forecast

9 Market Breakup by End User

9.1 Hospitals
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
9.2 Ambulatory Surgical Center
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
9.3 Others
- 9.3.1 Market Trends
- 9.3.2 Market Forecast

10 Market Breakup by Region

10.1 North America
- 10.1.1 United States
  - 10.1.1.1 Market Trends
  - 10.1.1.2 Market Forecast
- 10.1.2 Canada
  - 10.1.2.1 Market Trends
  - 10.1.2.2 Market Forecast
10.2 Asia-Pacific
- 10.2.1 China
  - 10.2.1.1 Market Trends
  - 10.2.1.2 Market Forecast
- 10.2.2 Japan
  - 10.2.2.1 Market Trends
  - 10.2.2.2 Market Forecast
- 10.2.3 India
  - 10.2.3.1 Market Trends
  - 10.2.3.2 Market Forecast
- 10.2.4 South Korea
  - 10.2.4.1 Market Trends
  - 10.2.4.2 Market Forecast
- 10.2.5 Australia
  - 10.2.5.1 Market Trends
  - 10.2.5.2 Market Forecast
- 10.2.6 Indonesia
  - 10.2.6.1 Market Trends
  - 10.2.6.2 Market Forecast
- 10.2.7 Others
  - 10.2.7.1 Market Trends
  - 10.2.7.2 Market Forecast
10.3 Europe
- 10.3.1 Germany
  - 10.3.1.1 Market Trends
  - 10.3.1.2 Market Forecast
- 10.3.2 France
  - 10.3.2.1 Market Trends
  - 10.3.2.2 Market Forecast
- 10.3.3 United Kingdom
  - 10.3.3.1 Market Trends
  - 10.3.3.2 Market Forecast
- 10.3.4 Italy
  - 10.3.4.1 Market Trends
  - 10.3.4.2 Market Forecast
- 10.3.5 Spain
  - 10.3.5.1 Market Trends
  - 10.3.5.2 Market Forecast
- 10.3.6 Russia
  - 10.3.6.1 Market Trends
  - 10.3.6.2 Market Forecast
- 10.3.7 Others
  - 10.3.7.1 Market Trends
  - 10.3.7.2 Market Forecast
10.4 Latin America
- 10.4.1 Brazil
  - 10.4.1.1 Market Trends
  - 10.4.1.2 Market Forecast
- 10.4.2 Mexico
  - 10.4.2.1 Market Trends
  - 10.4.2.2 Market Forecast
- 10.4.3 Others
  - 10.4.3.1 Market Trends
  - 10.4.3.2 Market Forecast
10.5 Middle East and Africa
- 10.5.1 Market Trends
- 10.5.2 Market Breakup by Country
- 10.5.3 Market Forecast

11 SWOT Analysis

11.1 Overview
11.2 Strengths
11.3 Weaknesses
11.4 Opportunities
11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

13.1 Overview
13.2 Bargaining Power of Buyers
13.3 Bargaining Power of Suppliers
13.4 Degree of Competition
13.5 Threat of New Entrants
13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

15.1 Market Structure
15.2 Key Players
15.3 Profiles of Key Players
- 15.3.1 Aerie Pharmaceuticals Inc.
  - 15.3.1.1 Company Overview
  - 15.3.1.2 Product Portfolio
  - 15.3.1.3 Financials
- 15.3.2 Bausch Health Companies Inc.
  - 15.3.2.1 Company Overview
  - 15.3.2.2 Product Portfolio
  - 15.3.2.3 Financials
  - 15.3.2.4 SWOT Analysis
- 15.3.3 Bayer AG
  - 15.3.3.1 Company Overview
  - 15.3.3.2 Product Portfolio
  - 15.3.3.3 Financials
  - 15.3.3.4 SWOT Analysis
- 15.3.4 F. Hoffmann-La Roche Ltd
  - 15.3.4.1 Company Overview
  - 15.3.4.2 Product Portfolio
  - 15.3.4.3 Financials
- 15.3.5 Iveric Bio Inc.
  - 15.3.5.1 Company Overview
  - 15.3.5.2 Product Portfolio
  - 15.3.5.3 Financials
- 15.3.6 Novartis AG
  - 15.3.6.1 Company Overview
  - 15.3.6.2 Product Portfolio
  - 15.3.6.3 Financials
  - 15.3.6.4 SWOT Analysis
- 15.3.7 Panoptica
  - 15.3.7.1 Company Overview
  - 15.3.7.2 Product Portfolio
- 15.3.8 Pfizer Inc.
  - 15.3.8.1 Company Overview
  - 15.3.8.2 Product Portfolio
  - 15.3.8.3 Financials
  - 15.3.8.4 SWOT Analysis
- 15.3.9 Phio Pharmaceuticals
  - 15.3.9.1 Company Overview
  - 15.3.9.2 Product Portfolio
  - 15.3.9.3 Financials
- 15.3.10 Regeneron Pharmaceuticals Inc.
  - 15.3.10.1 Company Overview
  - 15.3.10.2 Product Portfolio
  - 15.3.10.3 Financials
  - 15.3.10.4 SWOT Analysis
- 15.3.11 Regenxbio Inc.
  - 15.3.11.1 Company Overview
  - 15.3.11.2 Product Portfolio
  - 15.3.11.3 Financials
  - 15.3.11.4 SWOT Analysis
- 15.3.12 Santen Pharmaceutical Co. Ltd.
  - 15.3.12.1 Company Overview
  - 15.3.12.2 Product Portfolio
  - 15.3.12.3 Financials
  - 15.3.12.4 SWOT Analysis